Nirsevimab shows 90% success in shielding infants from RSV h

Study demonstrated a 90% effectiveness of nirsevimab in preventing RSV-associated hospitalizations in infants, with a significant finding being the timely vaccination's role in offering protection.

Related Keywords

United States , , Centers For Disease , Vaccine Surveillance Network , Mortality Weekly Report , Early Estimate , Nirsevimab Effectiveness , Respiratory Syncytial Virus , New Vaccine Surveillance Network , Disease Control , Children , Ortality , Espiratory , Vaccine , Virus ,